CTIS2022-501957-35-00招募中1 期
Contribution of an antiviral drug (Valaciclovir) in the treatment of generalized periodontitis (stage III or IV and grade A, B or C): prospective, randomized and double blind clinical trial. - 20-API-02
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 142
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age = 18 years, Diagnosis of periodontitis induced by bacterial biofilms of dental plaque, generalized, stage III or IV and grade A, B or C, Patients of childbearing age will need to use an effective method of contraception for the duration of their study participation, Signature of informed consent, Membership of a social security scheme
排除标准
- •Necrotizing periodontitis, Renal failure (creatinine clearance < 60 ml/min), Systemic antibiotic therapy or any medication affecting the periodontal environment (systemic antibiotics, antiepileptics, immunosuppressants, calcium inhibitors) taken within 3 months of inclusion, Nephrotoxic medications (aminoglycosides, organoplatines, iodized contrast agents, methotrexate, pentamidine, foscarnet, ciclosporine and tacrolimus), Hypersensitivity to valaciclovir, aciclovir or one of the excipients, History of DRESS syndrome under valaciclovir treatment, Pathologies requiring prophylactic antibiotic therapy (which may influence treatment), Non-surgical periodontal treatment completed within 6 months prior to inclusion, Patients with enhanced protection, namely lactating women, persons deprived of liberty by judicial or administrative decision, persons over 18 under legal protection, Patients who do not accept conventional therapy (gingival debridement not covered by the social security system) performed in each centre, Periodontitis as a direct manifestation of systemic diseases, Major systemic pathologies (diabetes, HIV, cancers, immunocompromised patients), Negative serology for EBV: a blood test will be performed. The results will be communicated to the patient by the dental surgeon, Pregnant women: a blood pregnancy test will be carried out for women of reproductive age who do not have contraception. Results will be communicated to the patient by the dental surgeon
研究者
相似试验
进行中（未招募）
1 期
Impact of anti-cytomegalovirus (valganciclovir) treatment in the management of relapsing ulcerative colitis (UC) requiring vedolizumab therapy: a randomized clinical trial comparing a strategy with or without antiviral therapyPatient with active ulcerative colitis who failed to anti-TNF with endoscopic active disease with an endoscopic Mayo score> 1 and 2 biopsies of the inflammatory tissue and presence of a CMV infection in the inflammatory tissue objectified by a viral load greater than 5 IU / 100000 cells by qPCR.MedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.1Level: LLTClassification code 10058881Term: Cytomegalovirus viremiaSystem Organ Class: 100000004862EUCTR2019-001032-54-FRCHU de Saint Etienne120
已完成
不适用
Resarch of the effect of antiviral drugs on the suppression of COVID-19 persistent symptomsCOVID-19JPRN-UMIN000048380agasaki University382
招募中
不适用
Antiviral therapy with direct acting anti-virals in hepatitis C patients.Chronic hepatitis CJPRN-UMIN000016288Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine500
进行中（未招募）
1 期
VALIDATE: Effect of Valacyclovir in people with HIV and HSV-2 coinfectioEUCTR2011-002268-26-GBniversity Health Network, Toronto General Hospital480
已完成
不适用
Antiviral therapy (cidofovir, an acyclic nucleoside phosphate) in combination with radiotherapy in HPV-positive tumours of the oropharynx: a phase 1 study.NL-OMON33865Academisch Ziekenhuis Maastricht12